What is the EDCTP?

The European and Developing Countries Clinical Trials Partnership (EDCTP) exists to accelerate the clinical development of new or improved health technologies for the identification, treatment and prevention of poverty-related and neglected infectious diseases, including (re-)emerging diseases.

In addition, the EDCTP funds activities for research capacity building in Africa, supporting researchers’ careers and strengthening national health research systems.

Why is the partnership needed?

In the context of the Commission’s priorities of contributing to the United Nations Sustainable Development Goals, in particular Sustainable Development Goal 3, and the joint communication from the Commission entitled ‘Towards a Comprehensive Strategy with Africa’, the EU is committed to ensuring healthy lives and promoting well-being for all, to building an even stronger partnership between the two continents and to supporting the development of research and innovation capacities within Africa.

Moreover, the COVID-19 pandemic has revealed that, with the increased connectivity of different regions in the world, infectious diseases can rapidly spread all over the world. Developing health technologies is therefore crucial to limit the spread of such diseases, as well as to fight them once they have spread.

The new Global Health EDCTP3 Joint Undertaking

The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) builds on the first and second European and Developing Countries Clinical Trials Partnership programmes. This new joint undertaking is a partnership between the EU and the EDCTP Association, whose members are several European and African countries.

To decide on its scientific priorities and achieve its objectives, the GH EDCTP3 is to be advised by a Scientific Committee and other advisory bodies. The call for expression of interest for the selection of the members of the Scientific Committee is closed and the list of members will be available, when finalised, on this page.

The call for expression of interest for the selection of the members of the Stakeholders Group is now closed. The list of members will become available on this page once finalised.

Work Programme 2022

This is the first work programme under the Global Health EDCTP3 Joint Undertaking (GH EDCTP3).

Work Programme 2022

The Governing Board adopted the Global Health EDCTP3 Annual Work Programme on 3 May 2022. This document provides an overview of the work to be carried throughout the course of 2022, as well as other aspects of the establishment of the Joint Undertaking, such as the staff establishment plan and governance-related actions.

Work Programme 2022 is complemented with two annexes:

Annex 1: Calls for proposals in 2022

This annex includes all the calls for proposals launched in 2022. The call topics under this Work Programme are based on the Strategic Research and Innovation Agenda adopted by the Governing Board.

Annex 2: In-kind contributions to operational activities (IKAA) plan

This annex contains the plan of additional activities that the members of the EDCTP Association will carry out.

An Info day was held virtually on 02 June 2022 to present the Work Programme and its funding opportunities. The documents presented at this Info day as well as the recording of it can be found below under the Related Events section.

A Frequently Asked Questions (FAQ) document has been developed to provide further guidance on Work Programme 2022, such as on funding eligibility.

Focus and goals

This partnership will deliver new solutions for reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world.

By 2030, the GH EDCTP3 aims to develop and deploy at least two new technologies tackling infectious diseases, and support at least 100 research institutes in 30 countries to develop additional health technologies against infectious diseases.

EU contribution and budget

The total budget of the GH EDCTP3 JU will be of up to €1.6 billion. The EU’s financial contribution to the GH EDCTP3 Joint Undertaking will be €800 million. The EDCTP Association will contribute at least €400 million, and another €400 million is expected from other contributing partners, such as philanthropic organisations and industry.

The total funding for the previous EDCTP2 programme (2014-2020) was over €1.4 billion, with a contribution of €683 million from the EU.

Building up the Secretariat of the new Global Health EDCTP3 Joint Undertaking

The activities of the Global Health EDCTP3 Joint Undertaking are currently managed by the European Commission (DG Research and Innovation) under the lead of an interim Executive Director.

Recruitment of the staff of the Joint Undertaking has now started.

The vacancy for the permanent Executive Director is currently open for applications and a link can be found in the Official Journal of the European Union. Deadline for applications is 18 July 2022.

Applications for the first positions under the new Global Health EDCTP3 Joint Undertaking recently closed. Additional positions will be published in on this page and will be referenced on the EPSO Job opportunities portal.